Active COVID-19, Clinical Pathway — All Settings
Active COVID-19, Clinical Pathway — All Settings
Treatment of COVID-19 with Anti-SARS-CoV-2 Monoclonal Antibodies
Update 12/10/2022
Effective 12/10/2022, there are no monoclonal antibodies available for treatment of COVID-19 active against currently circulating SARS-CoV-2 variants. Bamlanivimab-etesevimab, casirivimab-imdevimab, sotrovimab, and bebtelovimab have all been deauthorized by the FDA given that they are not active.